{"classes":[{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the serum concentrations of BI 836909 were below limit of quantitation (BLQ) for 0.2 ug/day.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Geometric Coefficient of Variation could not be calculated because of the limited sample size.","groupId":"OG001","spread":"NA","value":"86.5"},{"groupId":"OG002","spread":"41.1","value":"90.8"},{"comment":"Geometric Coefficient of Variation could not be calculated because of the limited sample size.","groupId":"OG003","spread":"NA","value":"184"},{"groupId":"OG004","spread":"34.7","value":"526"},{"groupId":"OG005","spread":"67.3","value":"1070"},{"groupId":"OG006","spread":"34.6","value":"2180"},{"groupId":"OG007","spread":"30.7","value":"4130"},{"groupId":"OG008","spread":"55.4","value":"10700"},{"groupId":"OG009","spread":"47.6","value":"9810"},{"groupId":"OG010","spread":"121","value":"14100"},{"groupId":"OG011","spread":"54.3","value":"29900"},{"groupId":"OG012","spread":"41.0","value":"33000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"2"}],"units":"Participants"}],"description":"Serum concentration at steady state of BI 836909 (Css).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Intravenous infusion of BI 836909 (0.2 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG000","title":"Intravenous Infusion of BI 836909 (0.2 μg/d)"},{"description":"Intravenous infusion of BI 836909 (0.4 Microgram Per Day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable Adverse Events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG001","title":"Intravenous Infusion of BI 836909 (0.4 μg/d)"},{"description":"Intravenous infusion of BI 836909 (0.8 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG002","title":"Intravenous Infusion of BI 836909 (0.8 μg/d)"},{"description":"Intravenous infusion of BI 836909 (1.6 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG003","title":"Intravenous Infusion of BI 836909 (1.6 μg/d)"},{"description":"Intravenous infusion of BI 836909 (3.2 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG004","title":"Intravenous Infusion of BI 836909 (3.2 μg/d)"},{"description":"Intravenous infusion of BI 836909 (6.5 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG005","title":"Intravenous Infusion of BI 836909 (6.5 μg/d)"},{"description":"Intravenous infusion of BI 836909 (13 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles","id":"OG006","title":"Intravenous Infusion of BI 836909 (13 μg/d)"},{"description":"Intravenous infusion of BI 836909 (25 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG007","title":"Intravenous Infusion of BI 836909 (25 μg/d)"},{"description":"Intravenous infusion of BI 836909 (50 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG008","title":"Intravenous Infusion of BI 836909 (50 μg/d)"},{"description":"Intravenous infusion of BI 836909 (100 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG009","title":"Intravenous Infusion of BI 836909 (100 μg/d)"},{"description":"Intravenous infusion of BI 836909 (200 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG010","title":"Intravenous Infusion of BI 836909 (200 μg/d)"},{"description":"Intravenous infusion of BI 836909 (400 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG011","title":"Intravenous Infusion of BI 836909 (400 μg/d)"},{"description":"Intravenous infusion of BI 836909 (800 microgram per day (μg/d)). BI 836909 was administered as 4-week continuous intravenous infusion (c.i.v.) followed by a 2-week treatment break for 5 cycles or until progression, unacceptable adverse events, or any other reason necessitating withdrawal. In case of ongoing clinical benefit and if considered indicated by the investigator, 5 additional treatment cycles could be done, leading to a maximum of 10 cycles.","id":"OG012","title":"Intravenous Infusion of BI 836909 (800 μg/d)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Analysis Set (PKS): all evaluable patients in the treated set which provide at least one evaluable observation for at least one PK endpoint.","reportingStatus":"POSTED","timeFrame":"Pharmacokinetic samples were collected at 48:00 hours (h):minutes (min), 168:00, 336:00, 504:00 and 671:50 h after the start of infusion of BI 836909 of the first cycle.","title":"Serum Concentration at Steady State of BI 836909 (Css)","type":"SECONDARY","unitOfMeasure":"picogram/milliliter (pg/mL)"}